Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Allos Therapeutics, Inc.

  Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Allos
  Therapeutics, Inc.

Business Wire

SAN DIEGO -- May 01, 2012

Robbins Geller Rudman & Dowd LLP (“Robbins Geller”) today announced that a
class action has been commenced in the United States District Court for the
District of Colorado on behalf of all persons who held shares of the common
stock of Allos Therapeutics, Inc. (“Allos”) (NASDAQ:ALTH) on April 5, 2012,
against Allos, its Board of Directors and Spectrum Pharmaceuticals, Inc.
(“Spectrum”) for breaches of fiduciary duty in connection with the proposed
acquisition of Allos by Spectrum (the “Proposed Acquisition”) and for
violations of Section 14(e) of the Securities Exchange Act of 1934 (“1934
Act”) in connection with the Solicitation/Recommendation Statement on Schedule
14D-9 (“14D-9”) filed with the SEC on April 13, 2012.

If you wish to serve as lead plaintiff, you must move the Court no later than
60 days from today. If you wish to discuss this action or have any questions
concerning this notice or your rights or interests, please contact plaintiff’s
counsel, Darren Robbins of Robbins Geller at 800/449-4900 or 619/231-1058, or
via e-mail at Any member of the putative class may move the
Court to serve as lead plaintiff through counsel of their choice, or may
choose to do nothing and remain an absent class member.

Allos is a biopharmaceutical company that engages in the development and
commercialization of anti-cancer therapeutics, including FOLOTYN®, a folate
inhibitor for the treatment of patients with relapsed or refractory peripheral
T-cell lymphoma.

On April 5, 2012, Allos and Spectrum announced a definitive merger agreement
(the “Merger Agreement”) under which Allos would be acquired by Spectrum via
tender offer (the “Tender Offer”). Under the terms of the Merger Agreement,
upon successful completion of the Tender Offer, Allos stockholders will
receive $1.82 per share in cash plus one Contingent Value Right, which would
provide Allos stockholders with an additional payment of $0.11 per share in
cash if certain European regulatory approval and commercialization milestones
for FOLOTYN® are achieved.

The complaint alleges that the defendants directly breached their fiduciary
duties or aided and abetted breaches of fiduciary duties in connection with
the Proposed Acquisition, which significantly undervalues Allos and is the
result of an unfair sales process designed to ensure that only Spectrum has
the opportunity to acquire Allos. In addition, the complaint alleges that the
14D-9 contains material omissions and/or misstatements in contravention of
§14(e) of the 1934 Act and/or defendants’ fiduciary duty of disclosure under
state law, including material omissions and/or misstatements concerning the
sales process leading up to the execution of the Merger Agreement, the
Company’s value, the analyses performed by the Company’s financial advisor,
J.P. Morgan Securities LLC, and the potential and/or actual conflicts of
interest faced by J.P. Morgan. Without this material information, Allos
shareholders are prevented from making a fully-informed decision as to the
adequacy of the Tender Offer and whether to tender their shares.

Plaintiff seeks injunctive relief on behalf of all holders of Allos common
stock on April 5, 2012 (the “Class”). The plaintiff is represented by Robbins
Geller, which has expertise in prosecuting investor class actions and
extensive experience in actions involving financial fraud.

Robbins Geller represents U.S. and international investors and consumers in
contingency based complex litigation. With nearly 200 attorneys in nine
offices, the firm represents more institutional investors and pension funds in
securities and corporate litigation than any other law firm in the world. Not
only has the firm obtained six of the largest recoveries in history, but the
firm has been ranked number one in the number of shareholder class action
recoveries in MSCI’s Top SCAS 50 every year since 2003. According to
Cornerstone Research, the firm’s recoveries have averaged 35% above the median
for all firms over the past seven years (2005-2011). Please visit for more information.


Robbins Geller Rudman & Dowd LLP
Darren Robbins
800-449-4900 or 619-231-1058
Press spacebar to pause and continue. Press esc to stop.